RESUMO
BACKGROUND: Fixed drug eruptions (FDE) are characterized by recurrent, usually solitary erythematous or dark red macular, plaque or bullous lesions, all at the same site. Among the first choices for antidotal treatment in mercury exposure, 2,3-dimercapto-1-propanesulfonic acid (DMPS) is generally a drug with a low incidence of side effects. FDE due to DMPS was not detected in our literature research and so we aimed to present this rare case. CASE REPORT: Forty-eight-year-old male patient, gunpowder and explosives factory worker, was admitted to our hospital because of mercury exposure and we started DMPS treatment. On the second day of chelation treatment, swelling and felting on lips and complaints of wound formation in genital areas started. Annular, purple color plaque on penis with no angioedema was observed. Case was regarded as FDE. Systemic and topical steroid therapy was started after termination of chelation therapy and lesions regressed with steroids. DISCUSSION: Drug eruptions are substantially common dermatological problems and can be seen in about 2.2% of inpatients. The most common unexpected effects of DMPS are allergic skin reactions. The clinical state regress rapidly after the cessation of chelation therapy.
Assuntos
Quelantes/efeitos adversos , Toxidermias/tratamento farmacológico , Intoxicação por Mercúrio/tratamento farmacológico , Unitiol/efeitos adversos , Quelantes/uso terapêutico , Toxidermias/etiologia , Glucocorticoides/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Doenças do Pênis/induzido quimicamente , Doenças do Pênis/tratamento farmacológico , Unitiol/uso terapêuticoRESUMO
OBJECTIVE: To evaluate the efficacy and safety of gandouling plus sodium dimercaptosulphonate (DMPS) on neurological Wilson's disease (WD) in patients. METHODS: We retrospectively evaluated the clinical records of 125 WD patients with neurological syndromes who were treated with gandouling plus sodium DMPS or DMPS used alone. All patients had a history of neurological deterioration during their diseases courses. The clinical efficacies, adverse reactions, and results of the various hematological and biochemical investigations were recorded for statistical analysis. RESULTS: 92.30% (60 patients) of the WD patients treated with the combined therapy experienced an improved or stable neurological condition paralleled by a significantly improved GAS score. Meanwhile, the WBC and PLT counts stabilized, liver function and renal function were improved or remained stable. The combined therapy also obviously promoted the 24-h urinary copper excretion. In particular, only 30.76% of the WD patients experienced mild adverse reactions, including neurological deterioration in 5 patients (7.69%), hepatic worsening in 1 subject (1.89%), which was less frequently than those in the control group treated with DMPS only. CONCLUSION: Our findings indicate that the safety and efficacy of gandou-ling plus DMPS is superior to those of DMPS used alone in the WD patients with neurological symptoms.
Assuntos
Medicamentos de Ervas Chinesas/administração & dosagem , Degeneração Hepatolenticular/tratamento farmacológico , Unitiol/administração & dosagem , Adolescente , Adulto , China , Quimioterapia Combinada/efeitos adversos , Medicamentos de Ervas Chinesas/efeitos adversos , Feminino , Degeneração Hepatolenticular/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Unitiol/efeitos adversos , Adulto JovemRESUMO
In the present review we provide an update of the appropriate use of chelating agents in the treatment of intoxications with compounds of mercury, lead and copper. The relatively new chelators meso-2,3-dimercaptosuccinic acid (DMSA) and 2,3-dimercapto-propanesulphonate (DMPS) can effectively mobilize deposits of mercury as well as of lead into the urine. These drugs can be administered orally and have relatively low toxicity compared to the classical antidote dimercaptopropanol (BAL). d-Penicillamine has been widely used in copper overload, although 2,3-dimercaptosuccinic acid or tetrathiomolybdate may be more suitable alternatives today. In copper-toxicity, a free radical scavenger might be recommended as adjuvant to the chelator therapy.
Assuntos
Terapia por Quelação , Cobre , Medicina Baseada em Evidências , Intoxicação por Chumbo/tratamento farmacológico , Intoxicação por Mercúrio/tratamento farmacológico , Succímero/uso terapêutico , Unitiol/uso terapêutico , Administração Oral , Animais , Quelantes/administração & dosagem , Quelantes/efeitos adversos , Quelantes/uso terapêutico , Terapia por Quelação/efeitos adversos , Quimioterapia Combinada , Sequestradores de Radicais Livres/uso terapêutico , Humanos , Infusões Parenterais , Penicilamina/administração & dosagem , Penicilamina/efeitos adversos , Penicilamina/uso terapêutico , Succímero/administração & dosagem , Succímero/efeitos adversos , Trientina/administração & dosagem , Trientina/efeitos adversos , Trientina/uso terapêutico , Unitiol/administração & dosagem , Unitiol/efeitos adversosRESUMO
The aim of this study was to assess the clinical efficacy and safety of chelation treatment with penicillamine (PCA) in cross combination with sodium 2, 3-dimercapto-1-propane sulfonate (DMPS) repeatedly in patients with Wilson's disease (WD). Thirty-five patients with WD were enrolled. They were administrated intravenous DMPS in cross combination with oral PCA alternately which was practiced repeatedly, all with Zinc in the meantime. During the treatment, clinical observations and 24-h urine copper excretion as well as adverse effects of medicines were recorded and analyzed. Although the incidence of adverse effects was not significantly different after either intravenous DMPS or oral PCA treatment, levels of 24-h urine copper tended to be higher after short-term intravenous DMPS than that of oral PCA. Adverse effects in the course of intravenous DMPS were mainly neutropenia, thrombocytopenia, allergic reaction and bleeding tendency. As compared with oral PCA alone or intravenous DMPS alone, such repeated cross combination treatment could as much as possible avoid continued drug adverse effects or poor curative effect and had less chance to stop treatment in WD patients. Improved or recovered liver function in 71% of the patients, alleviated neurologic symptoms in 50% of the patients, and disappeared hematuria in 70% of the patients could be observed during the follow-up period of 6 months to 5 years after such combined chelation regimen. Chelation treatment repeatedly with oral penicillamine in cross combination with intravenous DMPS alternately could be more beneficial for WD patients to relieve symptoms, avoid continued drug adverse effects and maintain lifelong therapy.
Assuntos
Terapia por Quelação/métodos , Degeneração Hepatolenticular/tratamento farmacológico , Penicilamina/uso terapêutico , Unitiol/uso terapêutico , Administração Oral , Adolescente , Quelantes/administração & dosagem , Quelantes/efeitos adversos , Quelantes/uso terapêutico , Terapia por Quelação/efeitos adversos , Criança , Cobre/urina , Esquema de Medicação , Hipersensibilidade a Drogas/etiologia , Quimioterapia Combinada , Humanos , Injeções Intravenosas , Masculino , Neutropenia/induzido quimicamente , Tempo de Tromboplastina Parcial , Penicilamina/administração & dosagem , Penicilamina/efeitos adversos , Tempo de Protrombina , Trombocitopenia/induzido quimicamente , Fatores de Tempo , Resultado do Tratamento , Unitiol/administração & dosagem , Unitiol/efeitos adversosRESUMO
The purpose of this study was to determine the clinical efficacy of 2,3-dimercapto-1-propane sulfonic acid, Na salt, on the urinary excretion of mercury as well as its possible adverse effects. Ten men with occupational mercury exposure (urinary level of 50 micrograms/g creatinine or more) were assigned to receive 2,3-dimercapto-1-propane sulfonic acid p.o. (DIMAVAL capsules, 100 mg) 300 mg/d for five days. Informed written consent was obtained from each subject. Hematology analyses, blood, chemistry, and urinalysis were obtained at the start of the study, at the end of the 2,3-dimercapto-1-propane sulfonic acid treatment and 72 hours after the administration of the final dose of 2,3-dimercapto-1-propane sulfonic acid. Twenty-four-hour urine mercury levels were closely monitored throughout therapy. All data and measurements before and during drug doses were evaluated by analyses of variance. In all subjects mean urine mercury was significantly increased (p < .05) after pre-2,3-dimercapto-1-propane sulfonic acid treatment. One subject had a moderate hypersensitivity reaction (rash) to 2,3-dimercapto-1-propane sulfonic acid but no other toxic effects were observed.